Unquestionably, there is a common consensus regarding cardiorenal protection with renin-angiotensin-aldosterone system blockade (RAASB) in both diabetic and nondiabetic chronic kidney disease (CKD). Nevertheless, there remain conflicting retrospective reports regarding renal and cardiovascular mortality outcomes following discontinuation of RAASB in advanced CKD. We present an editorial on a recent article discussing renal and mortality outcomes among hospitalized veterans who were started back on RAASB versus those who were not started back on RAASB. The controversy surrounding this topic thickens as the analysis unfolds.
Keywords: ace inhibitor (acei); acute kidney injury (aki); angiotensin receptor blocker (arb); chronic kidney disease (ckd); late onset renal failure from angiotensin blockade (lorffab); renin-angiotensin-aldosterone system blockade (raasb).
Copyright © 2023, Onuigbo et al.